{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:04:49Z","timestamp":1781197489481,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jcf.2024.02.004","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T16:11:23Z","timestamp":1708704683000},"page":"436-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of lumacaftor\/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-3090","authenticated-orcid":false,"given":"Claire","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Volkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-6442","authenticated-orcid":false,"given":"Anna","family":"Zolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-6997","authenticated-orcid":false,"given":"Lutz","family":"Naehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pfleger (AT)","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lammertijn (BE)","family":"Elise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tje\u0161i\u0107-Drinkovi\u0107 (HR)","family":"Du\u0161ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u0159ev\u00ednek (CZ)","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr (CZ)","given":"Macek","family":"Milan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vebert Olesen (DK)","family":"Hanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senecal (FR)","family":"Nathalie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burgel (FR)","family":"Pierre-R\u00e9gis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fletcher (IE)","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padoan (IT)","family":"Rita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orenti (IT)","family":"Annalisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogi (IT)","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gambazza (IT)","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksejeva (LV)","family":"El\u012bna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charatsi (LU)","family":"Anna-Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zomer (NL)","family":"Domenique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakkeheim (NO)","family":"Egil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wo\u017aniacki (PL)","family":"Lukasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krivec (SI)","family":"Uro\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krantz (SE)","family":"Christina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindblad (SE)","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung (CH)","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarke (UK)","family":"Sarah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carr (UK)","family":"Siobh\u00e1n B\u2024","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.02.004_bib0001","series-title":"Annual Data Report","year":"2021"},{"key":"10.1016\/j.jcf.2024.02.004_bib0002","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.02.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2009.05.005","article-title":"Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening","volume":"155","author":"Stick","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2024.02.004_bib0004","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S2213-2600(13)70026-2","article-title":"Early lung disease in cystic fibrosis","volume":"1","author":"Grasemann","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2024.02.004_bib0005","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.02.004_bib0006","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4187\/respcare.06697","article-title":"Cystic fibrosis lung disease: an overview","volume":"65","author":"Turcios","year":"2020","journal-title":"Respir Care"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2024.02.004_bib0007","doi-asserted-by":"crossref","first-page":"eS8","DOI":"10.1016\/S0929-693X(20)30044-0","article-title":"CFTR gene variants, epidemiology and molecular pathology","volume":"27","author":"Bareil","year":"2020","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.jcf.2024.02.004_bib0008","unstructured":"The Clinical and Functional Translation of CFTR (CFTR2). US CF Foundation. Johns Hopkins University, The Hospital for Sick Children."},{"key":"10.1016\/j.jcf.2024.02.004_bib0009","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2024.02.004_bib0010","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2024.02.004_bib0011","first-page":"S5","article-title":"Increasing life expectancy in cystic fibrosis: advances and challenges","volume":"57","author":"McBennett","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.02.004_bib0012","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2213-2600(20)30517-8","article-title":"Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study","volume":"9","author":"Chilvers","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.02.004_bib0013","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.02.004_bib0014","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.02.004_bib0015","series-title":"European Cystic Fibrosis Society Patient Registry (ECFSPR) annual data report","author":"Zolin","year":"2021"},{"key":"10.1016\/j.jcf.2024.02.004_bib0016","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12931-023-02497-0","article-title":"The clinical impact of lumacaftor-ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting","volume":"24","author":"McNally","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.jcf.2024.02.004_bib0017","series-title":"Effects of Lumacaftor\/Ivacaftor on cystic fibrosis disease progression in children 2 through 5 years of age homozygous for F508del-CFTR: a phase 2 placebo-controlled clinical trial","author":"Stahl","year":"2023"},{"key":"10.1016\/j.jcf.2024.02.004_bib0018","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jcf.2019.12.006","article-title":"Lumacaftor\/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease","volume":"19","author":"Tong","year":"2020","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.02.004_bib0019","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/ppul.25250","article-title":"Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic","volume":"56","author":"Patel","year":"2021","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:30:54Z","timestamp":1777649454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1569199324000171"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of lumacaftor\/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}